Scancell Holdings has announced that its ImmunoBody vaccine, SCIB2, is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.

The treatment is being tested as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC), and works by activating the body’s immune system by enhancing the uptake and presentation of cancer antigens to help target and eliminate cancer cells.

The therapy targets an antigen called NY-ESO-1, which is expressed on a range of solid tumours, including NSCLC, oesophageal, ovarian, bladder and prostate cancers, neuroblastoma, melanoma and sarcoma.

The decision is based on pre-clinical studies that have demonstrated that administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.

On the back of the studies, Cancer Research UK are now planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

Scancell are “delighted” by the results, and excited “to announce this important milestone in our partnership with CancerResearch UK, which moves us one step closer to entering the clinic.

“This new nanoparticle approach to deliver SCIB2 is expected to achieve results that are as effective as, or even better than, electroporation. We believe SCIB2 has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours including NSCLC, the most frequent cause of cancer death globally.”

ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system and have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents.